Business Context and Reporting Period
Company: China SXT Pharmaceuticals, Inc.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: January 2026 (Specifically January 13, 2026)
Event: Completion of a registered direct offering of Class A ordinary shares and pre-funded warrants.
Key Financial Metrics
- Net Proceeds: Approximately $9,110,000 received from the offering.
- Offering Structure: Sale of 12,000,000 Class A ordinary shares and pre-funded warrants to purchase 54,666,666 Class A ordinary shares.
- Transaction Costs: Included placement agent fees (7.0% of gross proceeds), expense reimbursement (0.5% of gross proceeds), and out-of-pocket expenses capped at $100,000.
- Warrant Terms: Pre-funded warrants have an exercise price of $0.001 per share and are immediately exercisable subject to a 9.99% beneficial ownership limitation.
- Revenue, Profit, Cash Flow, Margins, Debt, Liquidity: The filing text does not provide a clear value for these operational financial metrics; it focuses solely on the capital raise transaction.
Material Changes
This filing reports a material capital event rather than a change in operational performance. The primary change is the increase in cash liquidity via the $9.11 million net proceeds and the expansion of the company's capital structure through the issuance of new shares and warrants. The filing does not provide comparative data against a prior period for revenue or earnings.
Guidance, Outlook, and Risks
- Use of Proceeds: The Company intends to use the net proceeds for general corporate purposes.
- Management Commentary: The offering was consummated on January 13, 2026, following a Securities Purchase Agreement dated January 9, 2026.
- Risks and Contingencies: The Pre-Funded Warrants include a beneficial ownership limitation (9.99%) which restricts exercise rights if exceeded. The warrants are subject to adjustment for stock splits, dividends, and combinations.
- Unusual Items: The transaction involved a significant issuance of pre-funded warrants (54.6 million) relative to the direct share issuance (12 million).
Investor Verification Checklist
- Verify the exact gross proceeds amount to calculate the total dilution impact of the 66,666,666 total potential shares (12M shares + 54.6M warrant shares).
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or redemption rights not detailed in the summary.
- Confirm the current share count outstanding to assess the immediate dilution percentage from the 12,000,000 new shares.
- Check subsequent filings for the actual deployment of the $9.11 million in net proceeds.